NEW YORK, May 20, 2014 (GLOBE NEWSWIRE) — New York- based securities law firm, Sichenzia Ross Friedman Ference LLP announced that it has represented Sorrento Therapeutics, Inc. (NASDAQ: SRNE), a late-stage clinical oncology company developing new treatments for cancer and its associated pain, in a $25.0 million public offering. The offering consists of 4,765,000 shares of common stock priced at $5.25 per share. The Sichenzia Ross Friedman Ference LLP team was led by partners Jeff Fessler and Marcelle Balcombe.
Media Contact
pr@srf.law
212-930-9700
Latest posts by Sichenzia Ross Ference Carmel LLP (see all)
- Sichenzia Ross Ference Carmel LLP Represents Sharps Technology in $400 Million Private Placement - August 28, 2025
- 美国思成律师事务所代表Dominari Securities、Pacific Century Securities和Revere Securities完成Curanex Pharmaceuticals纳斯达克上市 - August 27, 2025
- Sichenzia Ross Ference Carmel LLP Represents Dominari Securities in $15 Million Initial Public Offering of Curanex Pharmaceuticals - August 27, 2025